DE69110625D1 - Oxazolopyridinderivate, Verfahren zu ihrer Herstellung und die sie enthaltenden pharmazeutischen Zusammensetzungen. - Google Patents

Oxazolopyridinderivate, Verfahren zu ihrer Herstellung und die sie enthaltenden pharmazeutischen Zusammensetzungen.

Info

Publication number
DE69110625D1
DE69110625D1 DE69110625T DE69110625T DE69110625D1 DE 69110625 D1 DE69110625 D1 DE 69110625D1 DE 69110625 T DE69110625 T DE 69110625T DE 69110625 T DE69110625 T DE 69110625T DE 69110625 D1 DE69110625 D1 DE 69110625D1
Authority
DE
Germany
Prior art keywords
processes
preparation
pharmaceutical compositions
compositions containing
oxazolopyridine
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Fee Related
Application number
DE69110625T
Other languages
English (en)
Other versions
DE69110625T2 (de
Inventor
Gerald Guillaumet
Christine Flouzat
Michelle Devissaguet
Pierre Renard
Daniel Henri Caignard
Gerard Adam
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
ADIR SARL
Original Assignee
ADIR SARL
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by ADIR SARL filed Critical ADIR SARL
Application granted granted Critical
Publication of DE69110625D1 publication Critical patent/DE69110625D1/de
Publication of DE69110625T2 publication Critical patent/DE69110625T2/de
Anticipated expiration legal-status Critical
Expired - Fee Related legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D213/00—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
    • C07D213/02—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
    • C07D213/04—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D213/60—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D213/72—Nitrogen atoms
    • C07D213/74—Amino or imino radicals substituted by hydrocarbon or substituted hydrocarbon radicals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/04—Centrally acting analgesics, e.g. opioids
DE69110625T 1990-11-20 1991-11-20 Oxazolopyridinderivate, Verfahren zu ihrer Herstellung und die sie enthaltenden pharmazeutischen Zusammensetzungen. Expired - Fee Related DE69110625T2 (de)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
FR9014381A FR2669336B1 (fr) 1990-11-20 1990-11-20 Nouveaux derives d'oxazolo pyridines, leurs procedes de preparation et les compositions pharmaceutiques qui les contiennent.

Publications (2)

Publication Number Publication Date
DE69110625D1 true DE69110625D1 (de) 1995-07-27
DE69110625T2 DE69110625T2 (de) 1996-02-22

Family

ID=9402340

Family Applications (1)

Application Number Title Priority Date Filing Date
DE69110625T Expired - Fee Related DE69110625T2 (de) 1990-11-20 1991-11-20 Oxazolopyridinderivate, Verfahren zu ihrer Herstellung und die sie enthaltenden pharmazeutischen Zusammensetzungen.

Country Status (12)

Country Link
US (1) US5130311A (de)
EP (1) EP0487408B1 (de)
JP (1) JPH0735371B2 (de)
AT (1) ATE124047T1 (de)
AU (1) AU640289B2 (de)
CA (1) CA2055859A1 (de)
DE (1) DE69110625T2 (de)
FR (1) FR2669336B1 (de)
IE (1) IE914012A1 (de)
NZ (1) NZ240656A (de)
PT (1) PT99557A (de)
ZA (1) ZA919181B (de)

Families Citing this family (52)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR2663929A1 (fr) * 1990-06-29 1992-01-03 Adir Nouveaux derives d'oxazolo pyridines, leur procede de preparation et les compositions pharmaceutiques qui les contiennent.
US5618819A (en) * 1994-07-07 1997-04-08 Adir Et Compagnie 1,3-dihydro-2H-pyrrolo[2,3-b]pyridin-2-one and oxazolo[4,5-b]pyridin-2-(3H)-one compounds
KR100417489B1 (ko) 1997-12-22 2004-02-05 유로-셀티크 소시에떼 아노뉨 오피오이드 효능제／길항제 혼합물
US6228863B1 (en) * 1997-12-22 2001-05-08 Euro-Celtique S.A. Method of preventing abuse of opioid dosage forms
US6375957B1 (en) * 1997-12-22 2002-04-23 Euro-Celtique, S.A. Opioid agonist/opioid antagonist/acetaminophen combinations
DK1299104T3 (da) 2000-02-08 2009-08-03 Euro Celtique Sa Orale opioidagonistformuleringer sikret mod forfalskning
IL151058A0 (en) 2000-02-08 2003-04-10 Euro Celtique Sa Controlled-release compositions containing opioid agonist and antagonist
UA81224C2 (uk) 2001-05-02 2007-12-25 Euro Celtic S A Дозована форма оксикодону та її застосування
US20030065002A1 (en) 2001-05-11 2003-04-03 Endo Pharmaceuticals, Inc. Abuse-resistant controlled-release opioid dosage form
JP4256259B2 (ja) 2001-07-18 2009-04-22 ユーロ−セルティーク エス．エイ． オキシコドン及びナロキソンの医薬配合物
AU2002323032B2 (en) 2001-08-06 2005-02-24 Euro-Celtique S.A. Opioid agonist formulations with releasable and sequestered antagonist
US20030157168A1 (en) 2001-08-06 2003-08-21 Christopher Breder Sequestered antagonist formulations
US20030044458A1 (en) 2001-08-06 2003-03-06 Curtis Wright Oral dosage form comprising a therapeutic agent and an adverse-effect agent
US20030068375A1 (en) 2001-08-06 2003-04-10 Curtis Wright Pharmaceutical formulation containing gelling agent
CA2708900C (en) 2002-04-05 2019-06-04 Purdue Pharma Pharmaceutical preparation containing oxycodone and naloxone
AU2003270778B2 (en) 2002-09-20 2009-10-08 Alpharma Pharmaceuticals, Llc Sequestering subunit and related compositions and methods
WO2004032870A2 (en) * 2002-10-08 2004-04-22 Rinat Neuroscience Corp. Methods for treating post-surgical pain by admisnistering a nerve growth factor antagonist and compositions containing the same
US7255860B2 (en) 2002-10-08 2007-08-14 Rinat Neuroscience Corp. Methods for treating post-surgical pain by administering an anti-nerve growth factor antagonist antibody
UA80447C2 (en) * 2002-10-08 2007-09-25 Methods for treating pain by administering nerve growth factor antagonist and opioid analgesic
PT1575517E (pt) 2002-12-24 2012-05-28 Rinat Neuroscience Corp Anticorpos anti-ngf e métodos de utilização dos mesmos
US7569364B2 (en) * 2002-12-24 2009-08-04 Pfizer Inc. Anti-NGF antibodies and methods using same
US9498530B2 (en) 2002-12-24 2016-11-22 Rinat Neuroscience Corp. Methods for treating osteoarthritis pain by administering a nerve growth factor antagonist and compositions containing the same
US7655231B2 (en) * 2003-02-19 2010-02-02 Pfizer Inc. Methods for treating pain by administering a nerve growth factor antagonist and an NSAID
MY135852A (en) 2003-04-21 2008-07-31 Euro Celtique Sa Pharmaceutical products
EP2298303A1 (de) 2003-09-25 2011-03-23 Euro-Celtique S.A. Pharmazeutische kombinationen von hydrocodon und naltrexon
CA2562024C (en) 2004-04-07 2014-05-27 Rinat Neuroscience Corp. Methods for treating bone cancer pain by administering a nerve growth factor antagonist
EP1604666A1 (de) 2004-06-08 2005-12-14 Euro-Celtique S.A. Opioide zur Behandlung der chronischen obstruktiven Lungenkrankheit
PT1765292T (pt) 2004-06-12 2017-12-29 Collegium Pharmaceutical Inc Formulações de fármacos dissuasoras de abuso
CA2570048A1 (en) * 2004-07-07 2006-01-12 Medicure International Inc. Combination therapies employing platelet aggregation drugs
US7459468B2 (en) * 2004-10-28 2008-12-02 Medicure International, Inc. Aryl sulfonic pyridoxines as antiplatelet agents
US20060094749A1 (en) * 2004-10-28 2006-05-04 Medicure International Inc. Substituted pyridoxines as anti-platelet agents
JP2008517956A (ja) 2004-10-28 2008-05-29 メディキュア・インターナショナル・インコーポレーテッド 二重の抗血小板性／抗凝固性ピリドキシン類似体
EP1702558A1 (de) * 2005-02-28 2006-09-20 Euro-Celtique S.A. Verfahren und Vorrichtung zur Darmtätigkeitserfassung
MX2008016372A (es) 2006-06-19 2009-05-28 Alpharma Inc Composiciones farmaceuticas.
US8623418B2 (en) 2007-12-17 2014-01-07 Alpharma Pharmaceuticals Llc Pharmaceutical composition
WO2010071865A1 (en) 2008-12-19 2010-06-24 Nuon Therapeutics, Inc. Pharmaceutical compositions and methods for treating hyperuricemia and related disorders
US20100160351A1 (en) * 2008-12-19 2010-06-24 Nuon Therapeutics, Inc. Pharmaceutical compositions and methods for treating hyperuricemia and related disorders
PT2405915T (pt) 2009-03-10 2019-01-29 Euro Celtique Sa Composições farmacêuticas de libertação imediata compreendendo oxicodona e naloxona
WO2011032175A1 (en) 2009-09-14 2011-03-17 Nuon Therapeutics, Inc. Combination formulations of tranilast and allopurinol and methods related thereto
US10668060B2 (en) 2009-12-10 2020-06-02 Collegium Pharmaceutical, Inc. Tamper-resistant pharmaceutical compositions of opioids and other drugs
HUE058226T2 (hu) 2010-08-19 2022-07-28 Zoetis Belgium S A NGF elleni antitestek és alkalmazásuk
SG191288A1 (en) 2010-12-22 2013-07-31 Purdue Pharma Lp Encased tamper resistant controlled release dosage forms
ES2581323T3 (es) 2010-12-23 2016-09-05 Purdue Pharma Lp Formas de dosificación oral sólida resistentes a alteraciones
PT2710039T (pt) 2011-05-20 2019-04-23 Alderbio Holdings Llc Composições anti-cgrp e a sua utilização
US9617334B2 (en) 2012-06-06 2017-04-11 Zoetis Services Llc Caninized anti-NGF antibodies and methods thereof
US9149533B2 (en) 2013-02-05 2015-10-06 Purdue Pharma L.P. Tamper resistant pharmaceutical formulations
US10751287B2 (en) 2013-03-15 2020-08-25 Purdue Pharma L.P. Tamper resistant pharmaceutical formulations
MY183489A (en) 2013-07-23 2021-02-22 Euro Celtique Sa A combination of oxycodone and naloxone for use in treating pain in patients suffering from pain and a disease resulting in intestinal dysbiosis and/or increasing the risk for intestinal bacterial translocation
JP7116685B2 (ja) 2016-04-15 2022-08-10 エイチ． ルンドベック アー／エス ヒト化抗ｐａｃａｐ抗体及びそれらの使用
US9737530B1 (en) 2016-06-23 2017-08-22 Collegium Pharmaceutical, Inc. Process of making stable abuse-deterrent oral formulations
RU2020129265A (ru) 2018-03-12 2022-04-12 ЗОИТИС СЕРВИСЕЗ ЭлЭлСи Антитела против ngf и связанные с ними способы
CN117813325A (zh) 2021-08-27 2024-04-02 H.隆德贝克有限公司 使用抗cgrp抗体治疗丛集性头痛

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3929809A (en) * 1970-06-26 1975-12-30 Ciba Geigy Corp Oxazolo-{8 4,5-b{9 -pyridine-2-ones and -2-thiones as intermediates
GB8601160D0 (en) * 1986-01-17 1986-02-19 Fujisawa Pharmaceutical Co Heterocyclic compounds
FR2650591B1 (fr) * 1989-08-07 1991-11-15 Science Organisation Nouveaux derives d'oxazolo pyridines, leur procede de preparation et les compositions pharmaceutiques qui les contiennent
FI912926A (fi) * 1990-06-18 1991-12-19 Merck & Co Inc Inhibitorer av hiv-reverstranskriptas.
IL98526A0 (en) * 1990-06-18 1992-07-15 Merck & Co Inc Pyridones,processes for their preparation and pharmaceutical compositions containing them

Also Published As

Publication number Publication date
JPH0735371B2 (ja) 1995-04-19
ZA919181B (en) 1992-08-26
AU8794291A (en) 1992-05-21
EP0487408B1 (de) 1995-06-21
ATE124047T1 (de) 1995-07-15
PT99557A (pt) 1992-10-30
DE69110625T2 (de) 1996-02-22
FR2669336B1 (fr) 1993-01-22
NZ240656A (en) 1992-11-25
JPH04283566A (ja) 1992-10-08
CA2055859A1 (fr) 1992-05-21
EP0487408A1 (de) 1992-05-27
FR2669336A1 (fr) 1992-05-22
AU640289B2 (en) 1993-08-19
US5130311A (en) 1992-07-14
IE914012A1 (en) 1992-05-20

Similar Documents

Publication Publication Date Title
DE69110625T2 (de) Oxazolopyridinderivate, Verfahren zu ihrer Herstellung und die sie enthaltenden pharmazeutischen Zusammensetzungen.
ATE128458T1 (de) Naphtylalkylamine, verfahren zu ihrer herstellung und diese enthaltende pharmazeutische zusammensetzungen.
ATE40368T1 (de) Xanthin-derivate, verfahren zu ihrer herstellung und diese enthaltende pharmazeutische zusammensetzungen.
DE69415373D1 (de) Pyridothiadiazine, Verfahren zu ihrer Herstellung und sie enthaltende pharmazeutische Zusammensetzungen
ZA936658B (en) Benzopyran compounds process for their preparation and the pharmaceutical compositions which contain them
ATE100464T1 (de) Peptid-derivate, verfahren zu deren herstellung und diese enthaltende pharmazeutische zusammensetzungen.
ATE145899T1 (de) Trimetazidinederivate, verfahren zu deren herstellung und deren pharmazeutischen zusammensetzungen
ATE152707T1 (de) Neue naphthalin-amide und sulfonamide, verfahren zu ihrer herstellung und sie enthaltende pharmazeutische zusammensetzungen
ATE193531T1 (de) Phenyl-carboxamide-isoxazole-derivate und salze, verfahren zu ihrer herstellung ihre anwendung als arzneimittel und pharmazeutische zusammensetzungen die sie enthalten
ATE172976T1 (de) 3-aminochroman-spiroderivate, verfahren zu deren herstellung und diese enthaltende pharmazeutische zusammensetzungen
ATE214051T1 (de) Substituierte tetrahydropyridinderivate, verfahren zu ihrer herstellung und diese enthaltende arzneimittel
DE69300296T2 (de) Thiochromanderivate, Verfahren zu ihrer Herstellung und diese enthaltende pharmazeutische Zubereitungen.
AU639154B2 (en) New imidazole compounds, a process for the preparation thereof, and pharmaceutical compositions containing them
DE69300197T2 (de) Aminoalkylchromone, Verfahren zu ihrer Herstellung und diese enthaltende Zusammensetzungen.
DE69400283D1 (de) (Cyclohexyl)alkenderivate, Verfahren zu deren Herstellung und diese enthaltende pharmazeutische Zusammensetzungen
DE69403606D1 (de) Cyclizierte Analoge der Fettsäurenmetaboliten, Verfahren zu ihrer Herstellung und diese enthaltende pharmazeutische Zusammensetzungen
ATE82289T1 (de) 1-hydroxyalkylxanthine, verfahren zu ihrer herstellung und sie enthaltende medikamente.
ZA933942B (en) Pyrrolothienopyrazine compounds, processes for the preparation thereof and pharmaceutical compositions containing them

Legal Events

Date Code Title Description
8364 No opposition during term of opposition
8339 Ceased/non-payment of the annual fee